Clinical Trial Update: SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating SECOX as neoadjuvant therapy for locally advanced hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• SECOX

Snippet

Sponsor: The University of Hong Kong | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED